No pain, no gain: Company-building French VC scores €250M for life sciences fund
In the Truffle Capital playbook, you either go big or go home.
The French VC firm does not bother with pitches from companies vying for investment — instead, it sources the raw material to build companies from scratch. On Wednesday, it unveiled a €250 million boost to invest in the life sciences, in particular, the realm of interventional medical devices.
The recipe for investment is arduous. The firm appraises about 1000 unpublished patent applications from the top 50 universities across the United States and Europe. After whittling the list to five per year, it goes about negotiating exclusive global licenses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.